Navigation Links
Complete Genomics Announces Its First Public Presentation at the 7th Annual BIO Investor Forum
Date:10/22/2008

MOUNTAIN VIEW, Calif., Oct. 22 /PRNewswire/ -- Complete Genomics Inc., a newly launched, third-generation human genome sequencing company, today announced the company's presentation at the 7th Annual BIO Investor Forum, which will be held in San Francisco, Oct. 29-31, 2008.

Dr. Clifford Reid, chairman, president and chief executive officer of Complete Genomics, will present on Wednesday, Oct. 29, at 2:45 p.m. in the Marina Room of the Palace Hotel, located at 2 New Montgomery Street in downtown San Francisco. He will discuss how Complete Genomics' scalable service model and proprietary technology advances will allow the company to introduce its sequencing service in Q2 2009 at a cost of $5,000 per genome.

About Complete Genomics

Founded in 2006, Complete Genomics is a California company that has developed a novel approach to sequencing human DNA. Complete Genomics plans to combine its proprietary third-generation DNA sequencing technology and its high-performance computing capabilities to create a human genome sequencing service that will deliver low-cost, high-quality data on an unprecedented scale. The company is currently building the world's largest human genome sequencing center. This development will allow pharmaceutical and biotechnology customers, for the first time, to conduct large-scale human genome studies that will help identify the genetic underpinnings of complex diseases and drug responses. For additional information about the company, please visit http://www.completegenomics.com.


'/>"/>
SOURCE Complete Genomics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. American Oriental Bioengineering Completes Two Acquisitions
2. Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. S*BIO Completes US$26 Million Equity Financing
5. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
6. CeNeRx BioPharma Completes $15 Million Series B Financing
7. eRT Completes Milestone 100th Thorough QT Study
8. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
9. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
10. Facet Solutions Completes Facet Joint and Disc Replacement Study
11. Complete Genomics Launches, Becomes Worlds First Large-Scale Human Genome Sequencing Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):